Tudor Investment Corp ET AL Boosts Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Tudor Investment Corp ET AL lifted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 11.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 536,122 shares of the company's stock after purchasing an additional 53,832 shares during the quarter. Tudor Investment Corp ET AL owned 0.26% of Cellebrite DI worth $11,811,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of CLBT. Juncture Wealth Strategies LLC grew its holdings in shares of Cellebrite DI by 0.8% during the fourth quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company's stock worth $1,322,000 after purchasing an additional 505 shares in the last quarter. TD Waterhouse Canada Inc. grew its holdings in shares of Cellebrite DI by 1.8% in the fourth quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock worth $1,046,000 after purchasing an additional 859 shares during the last quarter. Strategic Advisors LLC increased its position in shares of Cellebrite DI by 3.4% in the fourth quarter. Strategic Advisors LLC now owns 29,082 shares of the company's stock valued at $641,000 after acquiring an additional 950 shares during the period. Steward Partners Investment Advisory LLC grew its position in shares of Cellebrite DI by 12.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company's stock worth $299,000 after buying an additional 1,463 shares during the last quarter. Finally, Tower View Wealth Management LLC increased its position in Cellebrite DI by 1.3% during the 4th quarter. Tower View Wealth Management LLC now owns 132,307 shares of the company's stock valued at $2,915,000 after purchasing an additional 1,660 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Needham & Company LLC reiterated a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Finally, Lake Street Capital lifted their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI currently has an average rating of "Buy" and a consensus target price of $23.43.

Cellebrite DI Stock Performance

CLBT stock traded up $0.28 during mid-day trading on Friday, reaching $20.14. 762,064 shares of the stock traded hands, compared to its average volume of 1,421,025. Cellebrite DI Ltd. has a one year low of $10.25 and a one year high of $26.30. The stock has a market capitalization of $4.82 billion, a PE ratio of -14.49, a PEG ratio of 4.27 and a beta of 1.44. The business has a 50-day moving average price of $18.82 and a two-hundred day moving average price of $20.20.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.